uniQure to Participate in Upcoming Industry Conferences in November

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) announced its participation in key investor and scientific conferences. The 28th Annual Meeting of the Huntington Study Group will be held virtually from November 4-6, 2021, featuring Dr. David Cooper discussing AMT-130 clinical trials. Additionally, the Virtual Neuroscience 2021 conference takes place from November 8-11, with Dr. Valeria Crepel presenting novel gene therapy for temporal lobe epilepsy. Lastly, the Stifel 2021 Virtual Healthcare Conference is scheduled for November 15-17, including a fireside chat by CEO Matt Kapusta.

LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

• The 28^th Annual Meeting of the Huntington Study Group (Virtual), November 4 - 6, 2021
  
  
  • David Cooper, M.D., vice president of clinical research CNS, will present an overview of the ongoing clinical trials of AMT-130 in Huntington’s Disease, HD-GeneTRX-1 and -2, and participate in a Q&A session on Friday, November 5^th at 3:15 p.m. ET.
    
    
  • An encore poster presentation entitled, “Demographics and healthcare resource utilization (HRU) in US patients with Huntington’s Disease: data from the Huntington’s Disease Burden of Illness (HDBOI) study” will also be available to view at the Poster Pavilion to registered participants.
    
    
• Virtual Neuroscience 2021 – 50^th Annual Meeting, November 8 - 11, 2021
  
  
  • Corlieve academic collaborator, Valeria Crepel, Ph.D., will present an encore presentation “CL002, An AAV9 vector expressing engineered miRNA targeting knockdown of GluK2-containing kainite receptors as a novel gene therapy approach for treating intractable temporal lobe epilepsy” on Thursday, November 11^th at 10:00 a.m. ET, Session P152: Antiepileptic Therapies IV.
    
    
• Stifel 2021 Virtual Healthcare Conference, November 15 - 17, 2021
  
  
  • Members of uniQure’s management team, including Matt Kapusta, chief executive officer, will participate in virtual one-on-one investor meetings on Wednesday, November 17th.
    
    
  • A fireside chat with Mr. Kapusta will take place the same day from 10:40 to 11:10 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington's disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:		FOR MEDIA:
Maria E. Cantor	Chiara Russo	Tom Malone
Direct: 339-970-7536	Direct: 617-306-9137	Direct: 339-970-7558
m.cantor@uniQure.com	c.russo@uniQure.com	t.malone@uniQure.com

FAQ

What are the dates for the 28th Annual Meeting of the Huntington Study Group?

The 28th Annual Meeting of the Huntington Study Group will be held virtually from November 4-6, 2021.

Who will present at the Virtual Neuroscience 2021 conference?

Dr. Valeria Crepel will present at the Virtual Neuroscience 2021 conference, discussing a novel gene therapy approach for temporal lobe epilepsy.

When is the Stifel 2021 Virtual Healthcare Conference?

The Stifel 2021 Virtual Healthcare Conference is scheduled for November 15-17, 2021.

What company is participating in these conferences?

uniQure N.V. (NASDAQ: QURE) is participating in these conferences to discuss its gene therapy advancements.

What is AMT-130 in relation to Huntington’s Disease?

AMT-130 is a gene therapy currently in clinical trials for Huntington's Disease, which will be discussed by Dr. David Cooper during the Huntington Study Group meeting.